3 news items
Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer
CORT
HALO
MAIA
6 Jun 24
overall response rate (ORR) of 38% and a disease control rate (DCR) of 85% with the THIO + cemiplimab combination in third-line treatments
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing's Syndrome)
CORT
28 May 24
rapid and sustained improvements in hypertension and were 5.9 times more likely to maintain their hypertension response compared to patients receiving
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
CORT
8 Apr 24
– the day before, the day of and the day after they received nab-paclitaxel – exhibited improvements in progression-free survival, duration of response
- Prev
- 1
- Next